ArticleBMC biotechnology2026
Phyto mediated synthesis of copper oxide nanoparticles with Zingiber officinale: comprehensive bioactivity assessment against bacterial pathogens, cancer, and viruses.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Green-Synthesized Silver Nanoparticles fromNanomaterials (Basel, Switzerland) · 2026Article
- Green Fabrication and Characterization of Copper Oxide Nanoparticles Using C. Gigantea Leaf Extract and Their ROS-Mediated Anticancer Activity Against A549 Lung Cancer Cells.Cell biochemistry and biophysics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This work investigated the capacity of Zingiber officinale extract to synthesize copper oxide nanoparticles. Z. officinale extract is rich in diverse phytochemical constituents, as confirmed by GC–MS analysis. The synthesized CuO NPs were characterized using TEM, FTIR, XRD, SEM, and EDX analyses. CuO NPs exhibited antibacterial efficacy against various bacterial strains. The DPPH methodology was employed to evaluate the free radical scavenging capacity, yielding an IC₅₀ value of 244.5 µg/mL. The CuO NPs exhibited pronounced antibiofilm activity at 100 µg/mL, reducing biofilm formation by S. aureus (MRSA) and E. coli by 70.93% and 67.3%, respectively. In addition, they demonstrated substantial antidiabetic potential, inhibiting α-amylase and α-glucosidase by up to 90% and 84% at 1000 µg/mL, with corresponding IC₅₀ values of 46.42 µg/mL and 38.9 µg/mL, respectively. Furthermore, CuO NPs exhibited low toxicity toward Vero cells, with an IC₅₀ of 261 µg/mL and showed potential anticancer activity against the carcinoma cell lines CaCo2 and McF7, with IC₅₀ values of 84.4 and 168 µg/mL, respectively. At 125 µg/mL, CuO NPs inhibited HAV and HSV-1 by 37% and 41.1%, respectively. These multifaceted bioactivities highlight the potential of Z. officinale–mediated CuO NPs as promising candidates for therapeutic and biomedical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.